GB-115 is a two-amino-acid molecule designed at the Zakusov Institute of Pharmacology in Moscow as a retro-analogue of the brain peptide cholecystokinin-4.
Amounts reported for GB-115 are listed under Reported protocols, each with its source and study kind. No amount ladder is inferred from them. This is educational source context, not a protocol or recommendation.
Enter a target amount only from your own reviewed source. The calculator can convert it into concentration, volume and device markings, but it will not infer an amount from product availability or another compound.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
Human study rows are described per source under Reported protocols; they belong to their trial populations and are not a general amount.
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
What published studies and recent community write-ups report about amounts, timing and course length. 1 clinical, 4 preclinical and 1 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical1 row | |||||
| Clinical study in generalised anxiety disorder31 patients (22 women, 9 men) aged 22 to 53 with generalised anxiety disorder (ICD-10 F41.1) | Effective dose determined at 6 mg per day, given as 1 mg tablets | Daily, in divided tablets | Oral tablets | 21 daysNone described | Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova (PubMed)2019 |
| Run by the institute that developed the compound, this study reports a fast anxiolytic effect with a stimulating component, benefit for sleep and autonomic symptoms, and improvement in attention and reaction time. The authors note that, unlike the SSRIs and SNRIs used first line, GB-115 did not cause early overactivation or worsened sleep. There was no placebo arm described in the abstract and the sample is small, so this is a dose-finding and tolerability report rather than proof of efficacy. | |||||
| Preclinical4 rows | |||||
| Oral anxiolytic dose range in rodentsOutbred mice and rats and inbred BALB/c mice with different stress-response phenotypes | 0.1-5.0 mg/kg by mouth (0.006-0.100 mg/kg when injected into the abdomen) | Single administration per test | Oral, compared against intraperitoneal | Not stated | Bulletin of Experimental Biology and Medicine (PubMed)2013 |
| Switching from injection to oral dosing moved the active range up by roughly a factor of fifty, which is the clearest published statement of how much of this compound survives the gut. Effects appeared in the open field and elevated plus maze and tracked the animal's emotional phenotype rather than the dose alone. These are rodent amounts and do not convert to a human amount. | |||||
| Preclinical safety packageMice, rats and rabbits, including reproductive and developmental arms | Acute oral doses up to 6000 mg/kg in mice and 3500 mg/kg in rats; 0.1 and 10 mg/kg for the chronic arm | Single acute doses, then daily for the chronic arm | Oral | 6 months for the repeat-dose armNot applicable | Eksperimentalnaia i Klinicheskaia Farmakologiia (PubMed)2010 |
| No animals died at the top acute doses, and six months of dosing produced no irreversible organ changes, no allergenic, immunotoxic or mutagenic signal and no effect on fertility or offspring development. The same work records suppression of a concanavalin A inflammatory response at 10 mg/kg. This is an animal toxicology file, not human safety data. | |||||
| Subchronic dosing in nonhuman primates4 male rhesus monkeys aged 5.7 to 6.7 years, individually caged | One 1 mg tablet daily, then two tablets daily (2 mg) | Once daily | Oral tablets | 7 days at one tablet, then 7 days at twoBehaviour was also scored after withdrawal | Doklady Biochemistry and Biophysics (PubMed)2025 |
| Both GB-115 and the benzodiazepine comparator phenazepam reduced time spent in the upper part of the cage, read as a lower stress response, and the 2 mg dose lowered the cortisol to DHEA-S ratio. Four animals is a very small sample, and the endpoint is observed behaviour plus two blood markers rather than a clinical outcome. | |||||
| Pharmacokinetics in animalsAnimals dosed by vein and by mouth, measured by high-performance liquid chromatography | Absolute oral bioavailability measured at 4.65 percent | Not stated | Intravenous compared against oral | Not stated | Bulletin of Experimental Biology and Medicine (PubMed)2007 |
| The dipeptide resisted breakdown by peptidases but still reached the bloodstream poorly by mouth, which is the mechanical reason oral animal doses sit so far above injected ones. The report gives the bioavailability figure rather than a dose, and no human pharmacokinetic study has been published. | |||||
| Community-reported1 row | |||||
| Vendor nasal spray kit | 200 mcg per spray, about 100 sprays per 10 mL bottle (20 mg total) | Not stated | Intranasal, supplied pre-mixed | Not stated | Community resource2026 |
| A vendor claim about what ships, and the reason this compound has nasal-spray support in the calculator. The lot certificate reports identity confirmed by HPLC and 0.2 mg measured against the 200 mcg label. The same page lists CAS 106321-44-2, which does not match the number PubChem carries for this structure (678996-63-9), so treat the vendor identity block with care. No published study has given GB-115 intranasally. | |||||
Plus 1 community resource (a dosing guide, forum thread or vendor write-up), reported above but not linked.
GB-115 is a two-amino-acid molecule designed at the Zakusov Institute of Pharmacology in Moscow as a retro-analogue of the brain peptide cholecystokinin-4, which means its glycine and tryptophan sit in reverse order relative to the natural fragment. It blocks central cholecystokinin receptors with low affinity, and Russian animal work reports anxiolytic, antidepressant-like and antinociceptive effects that depend on the animal's stress-response phenotype. One published clinical study in 31 patients with generalised anxiety disorder settled on 6 mg a day of a 1 mg tablet, and outside Russia the compound is sold only as a research chemical, including as a pre-mixed nasal spray.
These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.
Neuroplasticity, cognition, stress and sleep models.
Run by the institute that developed the compound, this study reports a fast anxiolytic effect with a stimulating component, benefit for sleep and autonomic symptoms, and improvement in attention and reaction time. The.
Switching from injection to oral dosing moved the active range up by roughly a factor of fifty, which is the clearest published statement of how much of this compound survives the gut. Effects appeared in the open.
No animals died at the top acute doses, and six months of dosing produced no irreversible organ changes, no allergenic, immunotoxic or mutagenic signal and no effect on fertility or offspring development. The same work.
Both GB-115 and the benzodiazepine comparator phenazepam reduced time spent in the upper part of the cage, read as a lower stress response, and the 2 mg dose lowered the cortisol to DHEA-S ratio. Four animals is a very.
The dipeptide resisted breakdown by peptidases but still reached the bloodstream poorly by mouth, which is the mechanical reason oral animal doses sit so far above injected ones. The report gives the bioavailability.
Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.
1 protocol row on this page come from human trials, trial registrations, regulator labels or reviews of human data. Approval status and populations are stated per row.
4 protocol rows describe animal, cell or toxicology work. Amounts from these rows do not translate to people.
1 row record what blogs, vendor write-ups or forums describe for GB-115. None has been verified against primary literature.
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Gly-Trp (N-terminal 6-phenylhexanoyl, C-terminal amide)
GB115, N-phenylhexanoyl-glycyl-L-tryptophan amide, N-(6-phenylhexanoyl)glycyl-L-tryptophanamide, UNII G5YT2F7SG8, DTXSID70461104
ZBIQNIJICMOVKN-QFIPXVFZSA-N
N-[2-[[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]-6-phenylhexanamide
7 curated references, each with its journal, year and study model, plus 1 community resource reported but not linked.